Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Nanosonics Limited Just Reported Profit Down 90%

Ultrasound probe disinfection company Nanosonics Limited (ASX: NAN) released its half year financial report to investors on Friday, showing a 90% decrease in profit.

Ultrasound probe disinfection company Nanosonics Limited (ASX: NAN) released its half year financial report to investors on Friday, showing a 90% decrease in profit.

Nanosonics describes itself as setting a new standard in ultrasound probe disinfection around the world with its trophon device.

Here are some of the highlights compared to last year:

  • Sales down 17% to $30 million
  • Gross profit down 15% to $22.3 million
  • Operating income before tax down 64% to $3.7 million
  • Profit down 90% to $2.2 million

Nanosonics CEO Michael Kavanagh said “In North America the strong adoption of trophon was maintained with a further 1,700 new units adopted in the half, growing the overall North American installed base to approximately 14,100 units.”

The company said that the reduction in sales was expected, mainly due to the GE Healthcare reduction of $1.8 million.

The company had an income tax benefit last year of $11.7 million, whereas this year it was a $1.5 million cost to Nanosonics.

Nanosonics increased its UK sales and service team as well as appointing a regional manager for Europe and the Middle East region. This is hoped to support the long-term growth strategy.

In the UK it increased its managed equipment service ‘MES’ installed base units by 86% in the half. MES is where the equipment is placed in hospitals for a contracted period and the facility pays for an all-inclusive price for consumables in return for the use and maintenance of the capital equipment.

The company said that the fundamentals for adoption across Europe also strengthened with the release of a number of new regulations including guidelines from the British Medical Ultrasound Society as well as the European Society of Radiology.

Mr Kavanagh said that in the second half of FY18 the company expects continued growth in North America similar to the first half and new unit growth in the UK of 75% to 100%.

Beyond FY18 Nanosonics expects strong growth of trophon in all installed core markets, expansion into new markets, a new GE Healthcare agreement and the introduction of new products including the second generation of trophon.

The Nanosonics share price has fallen 12.3% according to Google Finance.

Join Rask’s Investor Club Newsletter Today

You can join Rask’s FREE investor’s club newsletter today for all of the latest news and education on investing. Join today – it doesn’t cost a thing. BUT, you’ll need a good sense of humour and a willingness to learn.

Join today.

Keep Reading

 

Disclaimer: This article contains general information only. It is no substitute for licensed financial advice and should not be relied upon. By using our website you agree to our Disclaimer & Terms of Use and Privacy Policy

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content